Key result
ECG criteria for left ventricular hypertrophy are poor at identifying echocardiographic LVH in patients with type 2 diabetes.
Why the study?
Do ECG criteria accurately identify echocardiographic left ventricular hypertrophy in patients with type 2 diabetes?
Observational (n=219)
Do ECG criteria accurately identify echocardiographic left ventricular hypertrophy in patients with type 2 diabetes?
ECG criteria are insufficiently sensitive to detect echocardiographic left ventricular hypertrophy in diabetic patients, potentially leading to undertreatment if used as the sole screening tool for targeted therapies like ARBs.
Answers are grounded in this paper and cite their sources.
ECG criteria should not replace echo for LVH screening in type 2 diabetes; leaves open optimal detection strategies for targeted therapies.
OBJECTIVE: The Losartan Intervention For Endpoint Reduction (LIFE) study demonstrated a clear mortality benefit in treating hypertensive patients with electrocardiogram (ECG) evidence of left ventricular hypertrophy (LVH) with losartan rather than atenolol. Previous studies have also shown that identifying and treating echo LVH is associated with prognostic benefits in hypertensive subjects, and is independent of the presence of ECG LVH. We sought to determine how many cases of echo LVH would be missed by applying the ECG criteria for LVH used in the LIFE study. DESIGN: A prospective study of 219 patients with type 2 diabetes recruited from the hospital diabetic clinic. METHODS: Fifteen ECG criteria were assessed on each subject and compared with the presence or absence of LVH on echocardiography. RESULTS: All the proposed ECG criteria are poor at identifying echo LVH in people with diabetes. CONCLUSION: Using ECG LVH to select patients for angiotensin receptor blockade would lead to many diabetics with echo LVH missing out on the benefits of treatment. This assumes that the benefits seen in the LIFE study would also occur if the LIFE strategy were extended to echo LVH patients as well as to ECG LVH patients.
No takes yet. Share an insight, caveat, or question.
Dawson et al. (2004) conducted an observational in Type 2 diabetes (n=219). ECG criteria for left ventricular hypertrophy vs. Echocardiography was evaluated on Identification of echocardiographic left ventricular hypertrophy. ECG criteria for left ventricular hypertrophy are poor at identifying echocardiographic LVH in patients with type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: